stocks logo

DMAC

DiaMedica Therapeutics Inc
$
4.600
+0.06(1.322%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.6331
Open
4.560
VWAP
4.56
Vol
314.98K
Mkt Cap
197.26M
Low
4.350
Amount
1.44M
EV/EBITDA(TTM)
--
Total Shares
37.96M
EV
142.95M
EV/OCF(TTM)
--
P/S(TTM)
--
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.190
+46.15%
--
--
-0.197
+31.11%
--
--
-0.210
+16.67%
Estimates Revision
The market is revising No Change the revenue expectations for DiaMedica Therapeutics Inc. (DMAC) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 16.16%.
EPS Estimates for FY2025
Revise Upward
up Image
+2.24%
In Past 3 Month
Stock Price
Go Up
up Image
+16.16%
In Past 3 Month
3 Analyst Rating
up Image
128.26% Upside
Wall Street analysts forecast DMAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMAC is 10.50 USD with a low forecast of 10.00 USD and a high forecast of 11.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
128.26% Upside
Current: 4.600
sliders
Low
10.00
Averages
10.50
High
11.00
H.C. Wainwright
NULL -> Buy
upgrade
$10 -> $12
2025-07-18
New
Reason
H.C. Wainwright raised the firm's price target on DiaMedica Therapeutics to $12 from $10 and keeps a Buy rating on the shares. The firm says that with the positive interim results from Part 1a of the Phase 2 study, there is "tangible evidence" for the therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints from the dose escalation.
Lake Street
Buy
maintain
$11 -> $14
2025-07-18
New
Reason
Lake Street raised the firm's price target on DiaMedica Therapeutics to $14 from $11 and keeps a Buy rating on the shares after the company announced interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia that the firm sees "materially" improving the prospects for DM199 in this indication.
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$8 -> $11
2025-07-18
New
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on DiaMedica Therapeutics to $11 from $8 and keeps a Buy rating on the shares following interim results from Part 1a of its Phase 2 trial evaluating DM199 for preeclampsia. The data showed clinically meaningful reductions in both systolic and diastolic blood pressure, with the highest dose group experiencing acute drops of 35 mmHg and 15 mmHg respectively at 5 minutes. While the sample size remains small, the 24-hour average reductions of 20 mmHg systolic and 10 mmHg diastolic are encouraging and the firm says potentially clinically meaningful. These results support continued development into Part 1b and beyond, Craig-Hallum adds. Importantly, evidence suggests DM199 did not cross the placental barrier.
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Maintains
$7 → $10
2025-03-19
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$7
2024-11-15
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$7
2024-10-10
Reason

Valuation Metrics

The current forward P/E ratio for DiaMedica Therapeutics Inc (DMAC.O) is -5.77, compared to its 5-year average forward P/E of -5.00. For a more detailed relative valuation and DCF analysis to assess DiaMedica Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.00
Current PE
-5.77
Overvalued PE
-2.48
Undervalued PE
-7.53

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.83
Current EV/EBITDA
-3.41
Overvalued EV/EBITDA
-0.27
Undervalued EV/EBITDA
-5.38

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+41.86%
-8.14M
Operating Profit
FY2025Q1
YoY :
+49.62%
-7.71M
Net Income after Tax
FY2025Q1
YoY :
+28.57%
-0.18
EPS - Diluted
FY2025Q1
YoY :
+7.49%
-7.16M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
113.3K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

DMAC News & Events

Events Timeline

2025-07-21 (ET)
2025-07-21
09:19:59
DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement
select
2025-07-17 (ET)
2025-07-17
08:09:07
DiaMedica Therapeutics reports interim results from DM199 study
select
2025-06-24 (ET)
2025-06-24
09:08:40
DiaMedica Therapeutics to be included in Russell 2000, 3000 Indexes
select
Sign Up For More Events

News

4.0
07-18Benzinga
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11
4.0
07-18Benzinga
Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14
9.0
07-17Newsfilter
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
Sign Up For More News

FAQ

arrow icon

What is DiaMedica Therapeutics Inc (DMAC) stock price today?

The current price of DMAC is 4.6 USD — it has increased 1.32 % in the last trading day.

arrow icon

What is DiaMedica Therapeutics Inc (DMAC)'s business?

arrow icon

What is the price predicton of DMAC Stock?

arrow icon

What is DiaMedica Therapeutics Inc (DMAC)'s revenue for the last quarter?

arrow icon

What is DiaMedica Therapeutics Inc (DMAC)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for DiaMedica Therapeutics Inc (DMAC)'s fundamentals?

arrow icon

How many employees does DiaMedica Therapeutics Inc (DMAC). have?

arrow icon

What is DiaMedica Therapeutics Inc (DMAC) market cap?